European Union - English - EMA (European Medicines Agency)

jensonr+ limited - ivabradine hydrochloride - angina pectoris; heart failure - cardiac therapy - symptomatic treatment of chronic stable angina pectoris in coronary artery disease adults with normal sinus rhythm and heart rate ≥ 70 bpm. ivabradine is indicated: - in adults unable to tolerate or with a contra-indication to the use of beta-blockers - or in combination with beta-blockers in patients inadequately controlled with an optimal beta-blocker dose. treatment of chronic heart failure ivabradine is indicated in chronic heart failure nyha ii to iv class with systolic dysfunction, in patients in sinus rhythm and whose heart rate is ≥ 75 bpm, in combination with standard therapy including beta-blocker therapy or when beta-blocker therapy is contraindicated or not tolerated.,

European Union - English - EMA (European Medicines Agency)

les laboratoires servier - ivabradine hydrochloride - angina pectoris; heart failure - cardiac therapy - symptomatic treatment of chronic stable angina pectorisivabradine is indicated for the symptomatic treatment of chronic stable angina pectoris in coronary artery disease adults with normal sinus rhythm and heart rate ≥ 70 bpm. ivabradine is indicated:in adults unable to tolerate or with a contraindication to the use of beta-blockersor in combination with beta-blockers in patients inadequately controlled with an optimal beta-blocker dose.treatment of chronic heart failureivabradine is indicated in chronic heart failure nyha ii to iv class with systolic dysfunction, in patients in sinus rhythm and whose heart rate is ≥ 75 bpm, in combination with standard therapy including beta-blocker therapy or when beta-blocker therapy is contraindicated or not tolerated.

European Union - English - EMA (European Medicines Agency)

les laboratoires servier - ivabradine hydrochloride - angina pectoris; heart failure - cardiac therapy - symptomatic treatment of chronic stable angina pectoris ivabradine is indicated for the symptomatic treatment of chronic stable angina pectoris in coronary artery disease adults with normal sinus rhythm and heart rate ≥ 70 bpm. ivabradine is indicated :in adults unable to tolerate or with a contraindication to the use of beta-blockersor in combination with beta-blockers in patients inadequately controlled with an optimal beta-blocker dose.treatment of chronic heart failure ivabradine is indicated in chronic heart failure nyha ii to iv class with systolic dysfunction, in patients in sinus rhythm and whose heart rate is ≥ 75 bpm, in combination with standard therapy including beta-blocker therapy or when beta-blocker therapy is contraindicated or not tolerated.

European Union - English - EMA (European Medicines Agency)

"anpharm" przedsiębiorstwo farmaceutyczne s.a. - ivabradine - angina pectoris; heart failure - other cardiac preparations - symptomatic treatment of chronic stable angina pectorisivabradine is indicated for the symptomatic treatment of chronic stable angina pectoris in coronary artery disease adults with normal sinus rhythm and heart rate ≥ 70 bpm. ivabradine is indicated:in adults unable to tolerate or with a contra-indication to the use of beta-blockersor in combination with beta-blockers in patients inadequately controlled with an optimal betablocker dose.treatment of chronic heart failureivabradine is indicated in chronic heart failure nyha ii to iv class with systolic dysfunction, in patients in sinus rhythm and whose heart rate is ≥ 75 bpm, in combination with standard therapy including beta-blocker therapy or when beta-blocker therapy is contraindicated or not tolerated.

Malta - English - Medicines Authority

doc generici srl via turati, 40-20121, milano, italy - l - film-coated tablet - lacidipine 2 mg - calcium channel blockers

Malta - English - Medicines Authority

doc generici srl via turati, 40-20121, milano, italy - l - film-coated tablet - lacidipine 4 mg - calcium channel blockers

Malta - English - Medicines Authority

doc generici srl via turati, 40-20121, milano, italy - l - film-coated tablet - lacidipine 6 mg - calcium channel blockers

European Union - English - EMA (European Medicines Agency)

novartis europharm limited - brinzolamide - glaucoma, open-angle; ocular hypertension - ophthalmologicals - azopt is indicated to decrease elevated intraocular pressure in:ocular hypertension;open-angle glaucomaas monotherapy in adult patients unresponsive to beta-blockers or in adult patients in whom beta-blockers are contraindicated, or as adjunctive therapy to beta-blockers or prostaglandin analogues.

Israel - English - Ministry of Health

biotis ltd - terazosin as monohydrachloride dihydrate - tablets - terazosin as monohydrachloride dihydrate 5 mg - terazosin - terazosin - for symptomatic treatment of urinary obstruction caused by benign prostatic hypertrophy (bph). for mild to moderate hypertension.

Israel - English - Ministry of Health

biotis ltd - terazosin as monohydrachloride dihydrate - tablets - terazosin as monohydrachloride dihydrate 10 mg - terazosin - terazosin - for symptomatic treatment of urinary obstruction caused by benign prostatic hypertrophy (bph). for mild to moderate hypertension.